27 citations
,
October 2013 in “Experimental dermatology” Scleroderma patients have lower hair miR-29a levels.
21 citations
,
September 1990 in “Journal of The American Academy of Dermatology” Taking L-tryptophan supplements might cause a condition similar to scleroderma in some people, which can get better after stopping the supplement and starting corticosteroid therapy.
284 citations
,
November 1999 in “Neurology” The article suggests managing interferon beta therapy side effects in MS with dose adjustments, medications, and patient education.
37 citations
,
June 2004 in “Multiple Sclerosis Journal” The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
6 citations
,
May 2016 in “Multiple sclerosis and related disorders” Dimethyl-fumarate may cause temporary hair loss.
3 citations
,
September 2018 in “JAAD case reports” A Japanese man with rare skin conditions improved with hydroxychloroquine treatment.
3 citations
,
July 1985 in “British journal of dermatology/British journal of dermatology, Supplement” Autoimmune-related phenomena do not affect the progression or characteristics of lichen sclerosus in women.
May 2023 in “Journal of Investigative Dermatology” People with Lichen sclerosus are more likely to have skin conditions like vitiligo and alopecia areata, heart disease risks, and other health issues. They should be checked for these, but screening plans shouldn't differ based on gender due to lack of data.
March 2009 in “Journal of The American Academy of Dermatology” Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.
September 1961 in “Archives of Dermatology” Lichen sclerosus et atrophicus is generally not considered precancerous, but there are exceptions.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
40 citations
,
March 1984 in “Acta dermato-venereologica” Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.
20 citations
,
February 2017 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
10 citations
,
January 2003 in “Journal der Deutschen Dermatologischen Gesellschaft” Hydroxychloroquine helped improve scleromyxoedema in patients, but caused side effects in some.
8 citations
,
January 2019 in “Acta dermato-venereologica” Some children with localized scleroderma are rarely resistant to methotrexate, and no common profile for resistance was found.
5 citations
,
October 2015 in “British Journal of Dermatology” A certain medication improved severe itching in a boy with liver and bowel disease by reducing histamine levels, suggesting a new treatment target.
1 citations
,
November 2023 in “Life” Hyaluronic acid injections can improve mouth opening and quality of life in scleroderma patients.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
June 2023 in “Journal of The American Academy of Dermatology” Being overweight, having gallbladder removal surgery, and taking cholesterol-lowering drugs are linked to a higher chance of getting vulvar lichen sclerosus.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
July 2021 in “British Journal of Dermatology” A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.
June 2020 in “Annals of the Rheumatic Diseases” Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.
January 2015 in “British journal of medicine and medical research” A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.
February 2013 in “Biology of blood and marrow transplantation” Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.
March 2010 in “Journal of The American Academy of Dermatology” The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.
45 citations
,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
36 citations
,
December 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
14 citations
,
January 2019 in “Journal of Natural Medicines” Chaga mushrooms contain compounds that may promote hair growth better than common treatments.
12 citations
,
July 1957 in “Journal of Investigative Dermatology” Giving dihydrotachysterol to mother rats caused skin hardening and bone issues in their babies through milk.